Photo credit: NIH NCI Visuals Online
AstraZeneca and MSD (both UK) today announced that Lynparza® (olaparib) is now recommended for use within the Cancer Drugs Fund via the NHS in England as a treatment option for the BRCA mutation-positive, advanced high-grade epithelial ovarian, fallopian tube or primary peritneal cancer that has responded to first-line platinum-based chemotherapy in adults.